ClinicalTrials.gov
public full text
Public Domain
Ticagrelor Versus Cilostazol in Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever moderate and moderate to severe ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke#1008158
- Low-dose ticagrelor combined with aspirin in the prevention of early neurological deterioration of high-risk non-disabling ischemic cerebrovascular events: a PROBE clinical study.#214282
- Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke#840304
- Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke#1244498
- Outcomes in UK ACS Patients Prescribed Ticagrelor#1126866
Record · ID 1260197
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive